prototype 01
ClinicalTrials.gov-inspired scoring workflow for CTM shortlisting: input trial constraints, rank candidate sites, and inspect explainable score logic.
Score = 0.24*Experience + 0.18*Speed + 0.14*PI Capacity + 0.16*Competitor Exposure + 0.18*CTGov Relevance + 0.10*Stability + Sponsor Bonus
Sponsor Bonus = (SponsorFit - 50) * 0.12 when sponsor preference is enabled.
3
#1 Queen Mary Hospital
Hong Kong, Hong Kong
86.5
Tier 1
Queen Mary Hospital leads on TA/Indication Experience / Competitor Exposure / ClinicalTrials.gov Relevance, resulting in Tier 1 prioritization for feasibility shortlisting.
#2 Beijing Cancer Hospital
Beijing, China
74.7
Tier 2
Beijing Cancer Hospital leads on TA/Indication Experience / ClinicalTrials.gov Relevance / PI Capacity, resulting in Tier 2 prioritization for feasibility shortlisting.
#3 Henan Cancer Hospital
Zhengzhou, China
67.1
Henan Cancer Hospital leads on TA/Indication Experience / ClinicalTrials.gov Relevance / PI Capacity, resulting in Tier 2 prioritization for feasibility shortlisting.
#4 Zhejiang Cancer Hospital
Hangzhou, China
64.7
Tier 3
Zhejiang Cancer Hospital leads on TA/Indication Experience / ClinicalTrials.gov Relevance / PI Capacity, resulting in Tier 3 prioritization for feasibility shortlisting.
#5 Samsung Medical Center
Seoul, South Korea
50
Samsung Medical Center leads on Site Startup Speed / PI Capacity / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#6 Seoul National University Hospital
40.8
Seoul National University Hospital leads on PI Capacity / Site Startup Speed / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#7 Korea University Anam Hospital
36.5
Korea University Anam Hospital leads on PI Capacity / Execution Stability / Site Startup Speed, resulting in Tier 3 prioritization for feasibility shortlisting.
#8 Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Universitario Virgen Macarena leads on PI Capacity / Execution Stability / Site Startup Speed, resulting in Tier 3 prioritization for feasibility shortlisting.
#9 National Cheng Kung University Hospital
Tainan, Taiwan
36
National Cheng Kung University Hospital leads on PI Capacity / Execution Stability / Site Startup Speed, resulting in Tier 3 prioritization for feasibility shortlisting.
#10 National Taiwan University Hospital
Taipei, Taiwan
35.3
National Taiwan University Hospital leads on PI Capacity / Site Startup Speed / Competitor Exposure, resulting in Tier 3 prioritization for feasibility shortlisting.
#11 Hospital Universitario 12 de Octubre
Madrid, Spain
31.4
Hospital Universitario 12 de Octubre leads on PI Capacity / Competitor Exposure / Sponsor Fit, resulting in Tier 3 prioritization for feasibility shortlisting.
#12 Research Site
London, United Kingdom
27.9
Research Site leads on PI Capacity / Competitor Exposure / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#13 Songklanagarind Hospital
Songkhla, Thailand
26.6
Songklanagarind Hospital leads on PI Capacity / Competitor Exposure / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#14 Gustave Roussy
Villejuif, France
26.1
Gustave Roussy leads on PI Capacity / Competitor Exposure / Sponsor Fit, resulting in Tier 3 prioritization for feasibility shortlisting.
#15 Research Site
Berlin, Germany
25.1
Research Site leads on PI Capacity / Competitor Exposure / Sponsor Fit, resulting in Tier 3 prioritization for feasibility shortlisting.
#16 Hospital Universitari Vall d'Hebron
Barcelona, Spain
23
Hospital Universitari Vall d'Hebron leads on Execution Stability / Site Startup Speed / Competitor Exposure, resulting in Tier 3 prioritization for feasibility shortlisting.
#17 Virginia Cancer Specialists
Fairfax, United States
20.1
Virginia Cancer Specialists leads on Competitor Exposure / Sponsor Fit / PI Capacity, resulting in Tier 3 prioritization for feasibility shortlisting.
#18 TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2502)
Istanbul, Turkey (Türkiye)
19.1
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2502) leads on Competitor Exposure / Sponsor Fit / PI Capacity, resulting in Tier 3 prioritization for feasibility shortlisting.
#19 University General Hospital of Larissa
Larissa, Greece
15.1
University General Hospital of Larissa leads on Competitor Exposure / Sponsor Fit / PI Capacity, resulting in Tier 3 prioritization for feasibility shortlisting.
#20 UCLA Hematology/Oncology - Santa Monica ( Site 0023)
Los Angeles, United States
13.3
UCLA Hematology/Oncology - Santa Monica ( Site 0023) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#21 Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001)
Jacksonville, United States
Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#22 St. George Private Hospital ( Site 3004)
Kogarah, Australia
St. George Private Hospital ( Site 3004) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#23 Westmead Hospital ( Site 3000)
Westmead, Australia
Westmead Hospital ( Site 3000) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#24 Monash Health-Oncology Research ( Site 3001)
Clayton, Australia
Monash Health-Oncology Research ( Site 3001) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#25 Hospital Santa Rita de Cassia (Site 0449)
Vitória, Brazil
Hospital Santa Rita de Cassia (Site 0449) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#26 Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0447)
Natal, Brazil
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0447) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#27 Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0440)
Porto Alegre, Brazil
Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0440) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#28 William Osler Health System ( Site 0205)
Brampton, Canada
William Osler Health System ( Site 0205) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#29 Princess Margaret Cancer Centre ( Site 0204)
Toronto, Canada
Princess Margaret Cancer Centre ( Site 0204) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#30 Centro Investigacion Cancer James Lind ( Site 0513)
Temuco, Chile
Centro Investigacion Cancer James Lind ( Site 0513) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#31 Clinica Universidad Catolica del Maule-Oncology ( Site 0501)
Talca, Chile
Clinica Universidad Catolica del Maule-Oncology ( Site 0501) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#32 Centro de Estudios Clínicos SAGA (Site 0517)
Santiago, Chile
Centro de Estudios Clínicos SAGA (Site 0517) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#33 Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 1100)
Brno, Czechia
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 1100) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#34 Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni odd ( Site 1103)
Ostrava, Czechia
Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni odd ( Site 1103) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#35 Fakultni nemocnice Plzen ( Site 1104)
Pilsen, Czechia
Fakultni nemocnice Plzen ( Site 1104) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#36 Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1303)
Bordeaux, France
Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1303) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#37 CENTRE LEON BERARD ( Site 1305)
Lyon Cedex08, France
CENTRE LEON BERARD ( Site 1305) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#38 Universitaetsklinikum Freiburg ( Site 1405)
Freiburg, Germany
Universitaetsklinikum Freiburg ( Site 1405) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#39 Universitätsmedizin Göttingen - Georg-August-Universität-Klinik für Hämatologie und Medizinische On ( Site 1407)
Göttingen, Germany
Universitätsmedizin Göttingen - Georg-August-Universität-Klinik für Hämatologie und Medizinische On ( Site 1407) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#40 Errikos Dunant Hospital Center-Fourth Department of Oncology and Clinical Trials Unit ( Site 2705)
Athens, Greece
Errikos Dunant Hospital Center-Fourth Department of Oncology and Clinical Trials Unit ( Site 2705) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#41 THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 2700)
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 2700) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#42 Hong Kong Integrated Oncology Centre ( Site 3200)
Central, Hong Kong
Hong Kong Integrated Oncology Centre ( Site 3200) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#43 Queen Mary Hospital ( Site 3203)
Hksar, Hong Kong
Queen Mary Hospital ( Site 3203) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#44 Rambam Health Care Campus-Oncology Division ( Site 1702)
Haifa, Israel
Rambam Health Care Campus-Oncology Division ( Site 1702) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#45 Shaare Zedek Medical Center ( Site 1700)
Jerusalem, Israel
Shaare Zedek Medical Center ( Site 1700) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#46 Rabin Medical Center ( Site 1703)
Petah Tikva, Israel
Rabin Medical Center ( Site 1703) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#47 IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 1806)
Meldola, Italy
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 1806) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#48 Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1802)
Rome, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1802) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#49 Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800)
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#50 Aichi Cancer Center ( Site 3400)
Nagoya, Japan
Aichi Cancer Center ( Site 3400) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#51 Fujita Health University Hospital ( Site 3419)
Toyoake, Japan
Fujita Health University Hospital ( Site 3419) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#52 National Cancer Center Hospital East ( Site 3406)
Kashiwa, Japan
National Cancer Center Hospital East ( Site 3406) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#53 Hospital Raja Perempuan Zainab II-Medical Department ( Site 3502)
Kota Bharu, Malaysia
Hospital Raja Perempuan Zainab II-Medical Department ( Site 3502) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#54 National Cancer Institute-Radiotherapy and Oncology ( Site 3504)
Putrajaya, Malaysia
National Cancer Institute-Radiotherapy and Oncology ( Site 3504) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#55 Sarawak General Hospital-Radiotherapy Unit ( Site 3500)
Kuching, Malaysia
Sarawak General Hospital-Radiotherapy Unit ( Site 3500) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#56 CIO - Centro de Inmuno-Oncología de Occidente ( Site 0706)
Guadalajara, Mexico
CIO - Centro de Inmuno-Oncología de Occidente ( Site 0706) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#57 Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 0704)
Monterrey, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 0704) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#58 Centro de Investigacion Clinica de Oaxaca ( Site 0701)
Oaxaca City, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 0701) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#59 THE MEDICAL CITY ILOILO-The Medical City Iloilo - Clinical and Translational Research Institute-Ilo ( Site 3600)
Iloilo City, Philippines
THE MEDICAL CITY ILOILO-The Medical City Iloilo - Clinical and Translational Research Institute-Ilo ( Site 3600) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#60 Manila Doctors Hospital-Clinical Trial Office ( Site 3604)
Manila, Philippines
Manila Doctors Hospital-Clinical Trial Office ( Site 3604) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#61 Asian Hospital and Medical Center ( Site 3605)
Muntinlupa, Philippines
Asian Hospital and Medical Center ( Site 3605) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#62 Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2003)
Bydgoszcz, Poland
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2003) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#63 Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 2009)
Torun, Poland
Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 2009) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#64 Instytut Gruźlicy i Chorób Płuc w Warszawie ( Site 2011)
Warsaw, Poland
Instytut Gruźlicy i Chorób Płuc w Warszawie ( Site 2011) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#65 Chi Mei Medical Center ( Site 3910)
Chi Mei Medical Center ( Site 3910) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#66 Faculty of Medicine Siriraj Hospital ( Site 4000)
Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 4000) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#67 Lampang Cancer Hospital ( Site 4005)
Muang, Thailand
Lampang Cancer Hospital ( Site 4005) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#68 Medipol Mega Universite Hastanesi-oncology ( Site 2505)
Stanbul, Turkey (Türkiye)
Medipol Mega Universite Hastanesi-oncology ( Site 2505) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#69 Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2504)
Bornova, Turkey (Türkiye)
Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2504) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#70 ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2606)
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2606) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#71 St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 2600)
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 2600) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#72 Hanoi Oncology Hospital ( Site 4102)
Hanoi, Vietnam
Hanoi Oncology Hospital ( Site 4102) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#73 K Hospital - National Cancer Hospital ( Site 4105)
K Hospital - National Cancer Hospital ( Site 4105) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
#74 National Lung Hospital-Oncology Department ( Site 4104)
National Lung Hospital-Oncology Department ( Site 4104) leads on Competitor Exposure / Sponsor Fit / Execution Stability, resulting in Tier 3 prioritization for feasibility shortlisting.
Queen Mary Hospital
Hong Kong, Hong Kong · Tier: Tier 1
Total Score: 86.5
Why ranked high
startup median: 68 days
PI count: 5
matched profile count: 1
update log
2026-03-01 · v0.3.0
Live ClinicalTrials.gov Sync Connected